**Supplemental Table 1. Quantification of ENPP3 Expression in Various Carcinomas**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **RCC**  | **HCCN (%) of Samples** | **Colon Cancer N (%) of Samples** |
| **Intensity (H-Score)** | **ccRCC/TMA (N= 285)** | **pRCC/TMA(N = 25)** | **pRCC/Individual(N = 14)** | **TMA(N = 293)** | **Individual(N = 27)** | **Primary/TMA****(N = 32)** | **Metastatic/TMA(N = 21)** |
|  | **n (%)a** | **n (%)a** | **n (%)a** | **n (%)a**  | **n (%)a** | **n (%)a** | **n (%)a** |
| High (≥ 200 to 300) | 239 (83.9) | 6 (24.0) | 2 (14.3) | 8 (2.7) | 5 (18.5) | 0 | 0 |
| Moderate (≥ 100 to 199) | 19 (6.7) | 4 (16.0) | 7 (50) | 18 (6.1) | 6 (22.2) | 1 (3.1) | 0 |
| Low (≥ 15 to 99) | 9 (3.2) | 5 (20.0) | 3 (21.4) | 39 (13.3) | 9 (33.3) | 9 (28.1) | 3 (14.3) |
| Total positive staining | 267 (93.7) | 15 (60.0) | 12 (85.7) | 65 (22.2) | 20 (74.1) | 10 (31.3) | 3 (14.3) |

Abbreviations: ccRCC, clear cell renal carcinoma; pRCC, papillary renal cell carcinoma; TMA, tissue microarray. HCC, hepatocellular carcinoma

a Number and percentage of tested samples